CSIMarket
 


Rubius Therapeutics Inc   (RUBY)
Other Ticker:  
 

Cumulative Rubius Therapeutics Inc 's Working Capital Ratio for Trailing Twelve Months Period

RUBY's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

RUBY Working Capital Ratio for Trailing Twelve Months Period

(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
Y / Y Current Liabilities Growth -89.35 % 2.65 % 140.01 % -14.81 % 111.24 %
Y / Y Current Assets Growth -91.21 % -59.03 % -52.84 % -46.46 % 26.62 %
Working Capital Ratio for Trailing Twelve Months Period 13.19 14.82 18.48 26.38 28.93
Total Ranking # 1050 # 933 # 906 # 743 # 658
Seq. Current Liabilities Growth -85.87 % -29.9 % 2.9 % 4.42 % 36.27 %
Seq. Current Assets Growth -81.78 % -22.77 % -20.3 % -21.66 % -15.03 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2022
On the trailing twelve months basis Despite year on year decrease in Rubius Therapeutics Inc 's average Current Liabilities to $1 millions, Working Capital Ratio for Trailing Twelve Months Period to 13.19 below company average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 16 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Rubius Therapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about RUBY
Working Capital Ratio RUBY in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 17
Sector # 102
S&P 500 # 183


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
9.54 7.91 4.52
(Sep 30 2021)   (Dec 31 2022)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2022, within Biotechnology & Pharmaceuticals Industry Working Capital Ratio for Trailing Twelve Months Period
Aim Immunotech Inc   33.92 
Cabaletta Bio Inc   25.37 
Graphite Bio Inc   25.24 
Genenta Science S p a   23.89 
Tourmaline Bio Inc   23.41 
Vaxcyte Inc   23.37 
Protara Therapeutics Inc   22.19 
Cullinan Oncology Inc   22.05 
Aura Biosciences Inc   21.78 
Vor Biopharma Inc   21.57 
Replimune Group Inc   20.61 
Icosavax Inc   20.16 
Spk Acquisition Corp   19.38 
Relay Therapeutics Inc   19.33 
Cardiff Oncology inc   19.20 
Athira Pharma Inc   19.15 
Organovo Holdings Inc   17.33 
Fusion Pharmaceuticals Inc   17.03 
Crispr Therapeutics Ag  16.74 
Kymera Therapeutics Inc   16.63 
4d Molecular Therapeutics Inc   16.50 
Monte Rosa Therapeutics Inc   16.21 
Rubius Therapeutics Inc   16.10 
Candel Therapeutics Inc   15.79 
Achilles Therapeutics Plc  15.60 
Anavex Life Sciences Corp   15.53 
Forma Therapeutics Holdings Inc.  15.19 
Tarsus Pharmaceuticals Inc   15.14 
Compass Therapeutics Inc   13.52 
Century Therapeutics inc   13.51 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com